Showing 1 - 10 of 22
Persistent link: https://www.econbiz.de/10013173468
their innovation activities in response to the potential entry of direct competitors. We then examine a legal ruling that … firms increased their net innovation activities in response to competitive entry. These effects center on firms with … innovation by new entrants after the ruling in response to increased competition. Overall, these results are consistent with …
Persistent link: https://www.econbiz.de/10012818283
Persistent link: https://www.econbiz.de/10011742447
Persistent link: https://www.econbiz.de/10013461130
Biomedical innovation in oncology has become riskier and more expensive, precipitating a withdrawal of private sector …
Persistent link: https://www.econbiz.de/10012907810
their innovation activities in response to the potential entry of direct competitors. We then examine a legal ruling that … firms increased their net innovation activities in response to competitive entry. These effects center on firms with … innovation by new entrants after the ruling in response to increased competition. Overall, these results are consistent with …
Persistent link: https://www.econbiz.de/10012585448
For investment projects with low probabilities of success, long time horizons, and large capital requirements, traditional financing sources such as private and public equity may not be ideal. Nevertheless, such projects may yield attractive risk-adjusted returns when combined into a single...
Persistent link: https://www.econbiz.de/10013036066
Persistent link: https://www.econbiz.de/10012254271
Persistent link: https://www.econbiz.de/10012542757
We review the literature on financial intermediation in the process by which new medical therapeutics are financed, developed, and delivered. We discuss the contributing factors that lead to a key finding in the literature--underinvestment in biomedical R&D--and focus on the role that banks and...
Persistent link: https://www.econbiz.de/10013435156